Juan Albino Rodriguez, MD
Interventional Pain Medicine · Neenah, WINPI 1235226143
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Nevro Corp. accounts for 65.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $275 and has fallen 57.6% since, to $117 in 2024. That places this record below the midpoint for interventional pain medicine clinicians in WI, where the typical reported total is $2,684.
Across 17 payments — averaging $39.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$442
- Medtronic$114
- SPR Therapeutics, Inc$65
- GRT US Holding, Inc.$24
- Bioventus LLC$19
- Pacira Pharmaceuticals Incorporated$12
What the payments were for
- Food & beverage$675100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 11 | $442 |
| Medtronic | 2 | $114 |
| SPR Therapeutics, Inc | 1 | $65 |
| GRT US Holding, Inc. | 1 | $24 |
| Bioventus LLC | 1 | $19 |
| Pacira Pharmaceuticals Incorporated | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$675 in reported general payments places this provider in the 30th percentile of 41 interventional pain medicine providers in Wisconsin.
See all interventional pain medicine providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 98 | $1,496 |
| Pregabalin | 44 | $1,071 |
| Tramadol Hcl ErTramadol Hcl | 12 | $817 |
| Duloxetine Hcl | 39 | $524 |
| Baclofen | 13 | $370 |
| Methylprednisolone | 24 | $193 |
| Tramadol Hcl | 24 | $97 |
| Diclofenac Sodium | 12 | $94 |
| Cephalexin | 11 | $70 |
| Meloxicam | 28 | $65 |
| Diazepam | 24 | $21 |
| Alprazolam | 11 | $6 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Neenah
- Daniel BrunnerNeenah$24K
- Christopher HowsonGreen Bay$114K
- Matthew PileckiMount Pleasant$29K
- Christina MooreMilwaukee$26K
- Nileshkumar PatelGreenfield$25K
- Vishal Patelde Pere$23K
- Colin StairSummit$17K
- Timothy StaackeKenosha$13K
- Richard LennertzMilwaukee$11K
- Ryan ClarkGreen Bay$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.